The FDA has approved Wegovy (semaglutide 2.4 mg), Zepbound (tirzepatide), and Saxenda (liraglutide 3 mg) for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
Thats something that nutritional counseling has already been shown to do
En el informe 2019 del Instituto Nacional Central nico Coordinador de Ablacin e Implante (INCUCAI), la enfermedad renal diabtica contribuy al 36.6% de los ingresos a dilisis 1 , siendo tambin la causa ms frecuente de consulta nefrolgica en la actualidad en la mayora de los pases del mundo 2 , incluyendo Argentina
Here is where I point out that if we were focused on health from a weight-neutral paradigm instead of hoping that thinness will create health, we could stop intentionally promoting restrictive eating in the first place
Some swelling and bruising is normal, and minor bruising at the injection points can appear especially in patients with delicate skin
Though the FDA generally follows advisory panels recommendations, its unclear how the agency will act, particularly given that staff scientists have expressed their opposition to easing access to any of the peptides in question